---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-122076"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:48:03.680063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction

## Summary
- Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.
- 14 of 18 patients showed clinically meaningful improvement (≥4 points) on mNIS+7 at 24 months.
- 5 of 6 patients previously on patisiran and progressing achieved improvement on mNIS+7 at 24 months.
- Enrollment progressing well in Phase 3 MAGNITUDE-2 trial for ATTRv-PN; potential BLA submission by 2028.
- No new drug-related adverse events; most common were mild-to-moderate infusion reactions with no discontinuations.

## SEC filing metadata
- accession: 0001193125-25-122076
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/0001193125-25-122076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/d80735d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-122076
- JSON: https://secwatch.observer/filing/0001193125-25-122076.json
- Plain text: https://secwatch.observer/filing/0001193125-25-122076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.